The Persisting Burden of Intracerebral Haemorrhage: Can Effective Treatments Be Found?


article has not abstract


Published in the journal: . PLoS Med 7(10): e32767. doi:10.1371/journal.pmed.1000353
Category: Research in Translation
doi: 10.1371/journal.pmed.1000353

Summary

article has not abstract

Summary

Intracerebral haemorrhage (ICH) accounts for ∼10% and ∼20% of strokes in high and low-middle income countries, respectively, but ICH incidence and case fatality do not appear to be declining. Evidence supports organised stroke unit care and secondary prevention with blood pressure lowering after ICH. Ongoing randomised controlled trials of treatments that are either intended to limit early ICH growth, reduce perihaematomal oedema, or modify other key pathophysiological mechanisms underlying deterioration after acute ICH, offer hope for future improvements in outcome.

Introduction

Spontaneous intracerebral haemorrhage (ICH) that is apparently unrelated to trauma or an underlying vascular, neoplastic, or coagulopathic cause has incurred the same global burden over the past quarter of a century [1],[2]. During the last decade, spontaneous ICH accounted for ∼10% of strokes in high income countries and ∼20% of strokes in low and middle income countries, where the one month case fatalities were 25%–35% and 30%–48%, respectively [3].

The incidence of ICH is higher in Asians [2], and the major risk factors for spontaneous ICH without an identified cause (so-called primary ICH) are male gender, systemic arterial hypertension, excessive alcohol consumption, increasing age, smoking, and diabetes mellitus [4]. However, over the past quarter of a century, the incidence of primary ICH associated with pre-stroke hypertension seems to have declined, whereas there seems to have been an increase associated with antithrombotic use and presumed cerebral amyloid angiopathy in those aged ≥75 years [1]. Whilst primary prevention with antihypertensive medication is probably the most effective strategy to reduce the burden of ICH, could the management of ICH influence outcome?

The outcome after primary ICH seems to be worse than after a bleed secondary to an arteriovenous malformation [5], which justifies thorough investigation for all patients (Table 1). However, there is a shortage of evidence and lack of consensus about who, when, and how to further investigate for a cause underlying ICH [6]. There appears to be a modest association between ICH deep in the brain and hypertension, and between ICH in the lobes of the brain and cerebral amyloid angiopathy [7],[8], but these associations by no means rule out the need for further investigation of patients who are likely to survive and benefit from the identification of a treatable underlying cause (Table 1) [9].

Tab. 1. Investigations into Common Causes of Secondary Intracerebral Haemorrhage (ICH).
Investigations into Common Causes of Secondary Intracerebral Haemorrhage (ICH).
Full blood count, electrolytes, creatinine, urea, liver function tests, inflammatory markers (ESR/CRP), electrocardiogram, chest radiograph.

Apart from identifying and treating underlying causes of ICH, this review focuses on other strategies to improve outcome, bearing in mind the pathophysiological mechanisms underlying clinical deterioration after ICH. We go on to address the treatments for primary ICH that are supported by randomised controlled trials (RCTs) and those that are not, and discuss which interventions appear to be the most promising in ongoing and future RCTs.

Pathophysiology of Acute ICH

In humans, known pathophysiological mechanisms underlying further clinical deterioration soon after ICH include hydrocephalus, intraventricular extension of ICH, and recurrent ICH [10]; pathological and radiological studies have illuminated additional mechanisms (Figure 1). Human studies performing brain computed tomography within two time windows after ICH onset have documented haematoma expansion (Figure 2)—either due to growth of the original haemorrhage or re-bleeding [11][21]—that is associated with poor outcome [12],[16],[18],[22]. Imaging studies have demonstrated peri-haematomal hypoperfusion within the first week of ICH onset [23],[24], but not an “ischaemic penumbra” [25],[26]. However, there is evidence of a compensatory reduction in the metabolic rate, or a “metabolic penumbra”, around ICH [25],, as well as peri-haematomal hyperglycolysis (possibly due to inflammation, excitotoxicity, spreading depression, or seizures) [27]. Perihaematomal oedema appears to be vasogenic (plasma-derived) [28], its volume may increase within 24 hours of ICH onset and peak within 14 days [29][31], and it may be caused or exacerbated by thrombin and activated platelets [32],[33].

Selected pathophysiological mechanisms that have been identified in humans after acute, spontaneous intracerebral haemorrhage.
Fig. 1. Selected pathophysiological mechanisms that have been identified in humans after acute, spontaneous intracerebral haemorrhage.
Shapes are approximate illustrations of when pathophysiological mechanisms are at their peak and their known durations. Uncertainties about the duration and intensity of mechanisms are indicated by dashed lines.

Summary of selected radiological studies of spontaneous intracerebral haemorrhage growth.
Fig. 2. Summary of selected radiological studies of spontaneous intracerebral haemorrhage growth.
Studies are organised in ascending order of the duration of the time window of the first computed tomogram. Manual calculations of haematoma volume used the ABC/2 method. We excluded data on patients taking anticoagulant drugs in these studies, and excluded studies from which data could not be extracted [77],[78], studies that incorporated patients already included in the summary above [79],[80], or studies in which interventions may have influenced haematoma growth [58],[81].

Animal models support the contributions to peri-haematomal oedema made by clot retraction, hydrostatic pressure, enhanced thrombin production, increased blood–brain barrier permeability, and products of erythrocyte lysis (such as haeme oxygenase-mediated liberation of iron from haeme rings) [32],[34][37]. ICH in animal models seems to trigger humoral and cellular inflammatory responses: the consequent migration and recruitment of neutrophils and activation of native microglia results in oxidative stress and neuronal necrosis [38],[39], cytokines such as tumour necrosis factor α and interleukin 1-β lead to apoptosis [40],[41], complement activation causes erythrocyte lysis [42], and matrix metalloproteinases may result in oedema, necrosis, and blood–brain barrier disruption [43].

A better understanding of the pathophysiology of ICH could emerge if the decline in human autopsy rates reverses [44], and if animal models of ICH better represent human ICH [45]. Rodent models of ICH involve either stereotactic intraparenchymal infusion of autologous whole blood (which may cause simultaneous intraventricular or subarachnoid haemorrhage [46]), or injection of proteolytic bacterial collagenase (which incites a vigorous immune response in excess of that seen in humans [46]), after which very few animals die, which is quite unlike spontaneous ICH in humans [2].

Treatments Shown to Be Beneficial in Humans, Either in a Meta-Analysis of RCTs or in a Single Large RCT

A Cochrane meta-analysis of 31 RCTs involving 6,936 participants showed that organised inpatient care in stroke units benefits patients with stroke (whether ischaemic or due to ICH) by reducing the odds of death or dependency by 18% [47]. Large observational studies corroborate these findings in patients with ICH [48],[49]. Which aspects of organized stroke care, either individually or together, improve outcome in patients with ICH remain to be determined. One small, non-randomised, observational analysis, which was adjusted for some of the known influences on ICH prognosis, found survival after ICH to be better when managed in neuro-intensive care units compared to general intensive care units [50]: RCTs of some of the interventions used in the “black box” of neuro-intensive care (such as acute blood pressure lowering) are underway (see below). Furthermore, the benefits of standard care can be inferred from the effects on clinical outcome of do-not-resuscitate orders in a case-mix adjusted multi-hospital observational study [51], and withdrawal of care in a multivariable analysis at a single hospital [52].

A Cochrane meta-analysis of ten RCTs involving 2,059 participants found a reduction in death or dependence from the neurosurgical evacuation of spontaneous supratentorial ICH (odds ratio [OR] 0.71, 95% confidence interval [CI] 0.58 to 0.88) [53]. However, most of the RCTs included in this meta-analysis were of modest quality, their methods differed, and the largest RCT (Surgical Trial in Intracerebral Hemorrhage [STICH]) found no difference between early surgery or initial conservative management [54]. A sub-group with lobar ICH within 1 cm of the cortical surface appeared to benefit from surgery in STICH, so the STICH II RCT (ISRCTN 22153967) is evaluating early ICH evacuation in this sub-group of patients.

Secondary prevention with anti-hypertensive drugs reduced the risk of vascular events after stroke in the PROGRESS RCT; amongst the subset of 611 participants with ICH, the risk of subsequent stroke was halved by a perindopril-based blood pressure lowering regimen [55].

Treatments Neither Shown to be Beneficial to Humans in a Meta-Analysis of RCTs, Nor in a Single Large RCT

Haemostatic drugs are a biologically plausible intervention to improve outcome after ICH by limiting the early growth of spontaneous ICH (Figure 2). Despite the ability of recombinant activated factor VII (rFVIIa) to curtail early haematoma growth by 4–6 ml, a Cochrane meta-analysis of four RCTs involving 1,305 participants found that this surrogate outcome did not translate into any net clinical benefit (risk ratio of death or dependence [modified Rankin Scale score 4 to 6] at 90 days = 0.91 [95% CI 0.72 to 1.15]). This reduction in ICH growth may have been too small to improve clinical outcome, its benefit may have been offset by the thrombo-embolic adverse effects of rFVIIa, or the RCTs might have been unable to detect a small benefit of rFVIIa because of insufficient precision or some methodological weaknesses [56]. Other haemostatic drugs including antifibrinolytic agents seem to be worth testing in future RCTs.

Similarly, early blood pressure lowering might improve outcome after ICH by limiting the early growth of spontaneous ICH, but there has been a shortage of evidence supporting this intervention, unsurprisingly leading to differences between ICH guidelines [9],[57]. The Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial (INTERACT) randomized 404 patients presenting within 6 hours of onset to a systolic blood pressure target of ≤140 mmHg achieved within 1 hour and continued for 7 days, versus the American Heart Association guideline's target [9],[58]. There was a non-significant reduction in ICH growth by 1–2 ml, and no effect on clinical outcome, but the safety data are encouraging for the large, ongoing Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial (INTERACT-2; ISRCTN 73916115).

Attenuating peri-haematomal oedema might improve outcome after ICH (Figure 1), but meta-analyses have demonstrated neither benefit nor harm from dexamethasone (five RCTs involving 206 participants) [59], glycerol (two RCTs involving 224 participants) [60], and mannitol (two RCTs involving 149 participants) [61]. Neuroprotection, too, has caused neither benefit nor harm after acute ICH with the anti-oxidant free-radical scavenger NXY-059 (one RCT involving 607 participants) [62] or the glycine antagonist gavestinel (one RCT involving 571 participants) [63].

Future Directions

Attenuation of Haematoma Growth

The major treatment target of ongoing RCTs is haematoma growth, because ICH size and growth are determinants of outcome [12],. So far, the attenuation of early ICH growth seen with the haemostatic agent rFVIIa [56] or intensive acute blood pressure lowering [58],[64] has not improved clinical outcome in the RCTs performed. However, this biologically plausible mechanism for improving outcome is worthy of further research in RCTs that are large enough to detect small clinical benefits, such as the ongoing RCTs of acute blood pressure lowering (including INTERACT-2, the Efficacy of Nitric Oxide in Stroke Trial [ENOS; ISRCTN 99414122], Antihypertensive Treatment of Acute Cerebral Hemorrhage II [ATACH-II; ISRCTN R01-NS044976], and the Scandinavian Candesartan Acute Stroke Trial [SCAST; ISRCTN 13643354]). RCTs of alternative approaches to improve outcome after primary ICH by limiting haematoma expansion include rFVIIa in sub-groups of patients whose haematomas are more likely to grow (The Spot Sign for Predicting and Treating ICH Growth Study [STOP-IT; NCT00810888]), or testing the effectiveness of antifibrinolytic drugs such as the lysine analogue tranexamic acid, which seems to have attenuated ICH growth in two non-randomised studies [65],[66].

The greater risk of haematoma expansion and death after ICH associated with warfarin [67] and the contemporary increase in the incidence of primary ICH associated with all antithrombotic drugs [1] make RCTs of the management of antithrombotic-associated ICH a priority. Whilst stopping warfarin after ICH is common sense, and intravenous vitamin K administration is standard practice, there is a shortage of evidence about how else to treat anticoagulant-associated ICH [68], so RCTs comparing prothrombin complex concentrate with fresh frozen plasma in this context are ongoing (International Normalized Ratio (INR) Normalization in Coumadin Associated Intracerebral Haemorrhage [INCH; NCT00928915] and Efficacy and Safety of BERIPLEX P/N Compared with Plasma in Patients with Acute Major Bleeding Caused by Anticoagulant Therapy [NCT00708435]), as are studies of rFVIIa. The finding that mortality is higher for patients who were on antiplatelet agents at the time of ICH compared to those who were not [69] has led to an ongoing RCT of platelet transfusion to limit ICH growth and improve outcome after ICH associated with antiplatelet drugs (Platelet Transfusion in Cerebral Haemorrhage [PATCH; http://www.strokecenter.org/trials/TrialDetail.aspx?tid=730).

Other Approaches

Firstly, targeting other potentially treatable determinants of poor outcome after ICH may be fruitful. Intraventricular extension of ICH is one such mechanism [10], and there are two RCTs of ventricular drainage combined with intraventricular recombinant tissue plasminogen activator (Dutch Intraventricular Thrombolysis after Cerebral Haemorrhage Study [DITCH; ISRCTN 19105863] and Clot Lysis: Evaluation Acceleration of Resolution of IVH [CLEAR-IVH; NCT00650858]).

Secondly, just as the PATCH RCT is a response to the apparent rise in incidence of antiplatelet-associated ICH, the apparent rise in the incidence of lobar ICH that may be caused by cerebral amyloid angiopathy merits consideration of treatments that might reduce amyloid deposition [1]. Tramiprosate is a synthetic compound that competes with glycosaminoglycans for binding to β-amyloid peptide, reducing amyloid fibril formation and deposition, and demonstrated a good safety profile in a phase II study [70]. Amyloid-depleting agents, which have shown remarkable effects in Alzheimer's disease [71], are an alternative approach and may be preferable to amyloid-β immunisation, which can induce an immune-mediated encephalomyelitis [72].

Lastly, treatments that have proven beneficial in animal models might translate from the bench to the bedside, although there are concerns about the rodent ICH models used and the methodological quality of animal experiments [45],[46],[73]. One such example is deferoxamine (an iron-chelating agent that crosses the blood–brain barrier, and has been associated with a reduction in brain oedema, neurological deficits, and biochemical markers of oxidative damage in animals) [74],[75], which has led to the Dose Finding and Safety study of Deferoxamine in Patients with Brain Hemorrhage (DFO in ICH; NCT00598572).

Conclusions

The incidence and risk of dying from ICH seem not to have changed in recent decades, whilst the incidence of ischaemic stroke has declined [2],[3]. In contrast to the advances in the treatment of ischaemic stroke, stroke unit care and secondary prevention with blood pressure reduction are the only interventions for patients with stroke due to ICH that are based on robust evidence [47],[55]. However, insights gleaned from radiological and pathological investigations of the cause and pathophysiology of ICH, and the relentless pursuit of potential treatments in ongoing RCTs, are all cause for optimism [76].

Five Key Papers in the Field

  • van Asch CJ, Luitse MJ, Rinkel GJ, van der Tweel I, Algra A, et al. (2010) Incidence, case fatality, and functional outcome of intracerebral haemorrhage over time, according to age, sex, and ethnic origin: a systematic review and meta-analysis. Lancet Neurol 9(2): 167–176.

  • Davis SM, Broderick J, Hennerici M, Brun NC, Diringer MN, et al. (2006) Hematoma growth is a determinant of mortality and poor outcome after intracerebral hemorrhage. Neurology 66(8): 1175–1181.

  • Stroke Unit Trialists' Collaboration (2007) Organised inpatient (stroke unit) care for stroke. Cochrane Database Syst Rev (4): CD000197.

  • Chapman N, Huxley R, Anderson C, Bousser MG, Chalmers J, et al. (2004) Effects of a perindopril-based blood pressure-lowering regimen on the risk of recurrent stroke according to stroke subtype and medical history: the PROGRESS Trial. Stroke 35(1): 116–121.

  • NINDS ICH Workshop Participants (2005) Priorities for clinical research in intracerebral hemorrhage: report from a National Institute of Neurological Disorders and Stroke workshop. Stroke 36(3): e23–e41.


Zdroje

1. LovelockCE

MolyneuxAJ

RothwellPM

2007 Change in incidence and aetiology of intracerebral haemorrhage in Oxfordshire, UK, between 1981 and 2006: a population-based study. Lancet Neurol 6 487 493

2. van AschCJ

LuitseMJ

RinkelGJ

van der TweelI

AlgraA

2010 Incidence, case fatality, and functional outcome of intracerebral haemorrhage over time, according to age, sex, and ethnic origin: a systematic review and meta-analysis. Lancet Neurol 9 167 176

3. FeiginVL

LawesCM

BennettDA

Barker-ColloSL

ParagV

2009 Worldwide stroke incidence and early case fatality reported in 56 population-based studies: a systematic review. Lancet Neurol 8 355 369

4. AriesenMJ

ClausSP

RinkelGJ

AlgraA

2003 Risk factors for intracerebral hemorrhage in the general population: a systematic review. Stroke 34 2060 2065

5. van BeijnumJ

LovelockCE

CordonnierC

RothwellPM

KlijnCJ

2009 Outcome after spontaneous and arteriovenous malformation-related intracerebral haemorrhage: population-based studies. Brain 132 537 543

6. CordonnierC

KlijnCJ

van BeijnumJ

Al-Shahi SalmanR

2010 Radiological investigation of spontaneous intracerebral hemorrhage: systematic review and trinational survey. Stroke 41 685 690

7. RitterMA

DrosteDW

HegedusK

SzepesiR

NabaviDG

2005 Role of cerebral amyloid angiopathy in intracerebral hemorrhage in hypertensive patients. Neurology 64 1233 1237

8. JacksonCA

SudlowCL

2006 Is hypertension a more frequent risk factor for deep than for lobar supratentorial intracerebral haemorrhage? J Neurol Neurosurg Psychiatry 77 1244 1252

9. BroderickJ

ConnollyS

FeldmannE

HanleyD

KaseC

2007 Guidelines for the management of spontaneous intracerebral hemorrhage in adults: 2007 update: a guideline from the American Heart Association/American Stroke Association Stroke Council, High Blood Pressure Research Council, and the Quality of Care and Outcomes in Research Interdisciplinary Working Group. Stroke 38 2001 2023

10. QureshiAI

MendelowAD

HanleyDF

2009 Intracerebral haemorrhage. Lancet 373 1632 1644

11. BrottT

BroderickJ

KothariR

BarsanW

TomsickT

1997 Early hemorrhage growth in patients with intracerebral hemorrhage. Stroke 28 1 5

12. DavisSM

BroderickJ

HennericiM

BrunNC

DiringerMN

2006 Hematoma growth is a determinant of mortality and poor outcome after intracerebral hemorrhage. Neurology 66 1175 1181

13. JiN

LuJJ

ZhaoYL

WangS

ZhaoJZ

2009 Imaging and clinical prognostic indicators for early hematoma enlargement after spontaneous intracerebral hemorrhage. Neurol Res 31 362 366

14. FujitsuK

MuramotoM

IkedaY

InadaY

KimI

1990 Indications for surgical treatment of putaminal hemorrhage. Comparative study based on serial CT and time-course analysis. J Neurosurg 73 518 525

15. SansingLH

MesseSR

CucchiaraBL

CohenSN

LydenPD

2009 Prior antiplatelet use does not affect hemorrhage growth or outcome after ICH. Neurology 72 1397 1402

16. LeiraR

DavalosA

SilvaY

Gil-PeraltaA

TejadaJ

2004 Early neurologic deterioration in intracerebral hemorrhage: predictors and associated factors. Neurology 63 461 467

17. FujiiY

TakeuchiS

SasakiO

MinakawaT

TanakaR

1998 Multivariate analysis of predictors of hematoma enlargement in spontaneous intracerebral hemorrhage. Stroke 29 1160 1166

18. KazuiS

NaritomiH

YamamotoH

SawadaT

YamaguchiT

1996 Enlargement of spontaneous intracerebral hemorrhage. Incidence and time course. Stroke 27 1783 1787

19. KazuiS

MinematsuK

YamamotoH

SawadaT

YamaguchiT

1997 Predisposing factors to enlargement of spontaneous intracerebral hematoma. Stroke 28 2370 2375

20. OhwakiK

YanoE

NagashimaH

HirataM

NakagomiT

2004 Blood pressure management in acute intracerebral hemorrhage: relationship between elevated blood pressure and hematoma enlargement. Stroke 35 1364 1367

21. FlibotteJJ

HaganN

O'DonnellJ

GreenbergSM

RosandJ

2004 Warfarin, hematoma expansion, and outcome of intracerebral hemorrhage. Neurology 63 1059 1064

22. HemphillJCIII

BonovichDC

BesmertisL

ManleyGT

JohnstonSC

2001 The ICH score: a simple, reliable grading scale for intracerebral hemorrhage. Stroke 32 891 897

23. RosandJ

EskeyC

ChangY

GonzalezRG

GreenbergSM

2002 Dynamic single-section CT demonstrates reduced cerebral blood flow in acute intracerebral hemorrhage. Cerebrovasc Dis 14 214 220

24. PascualAM

Lopez-MutJV

BenllochV

ChamarroR

SolerJ

2007 Perfusion-weighted magnetic resonance imaging in acute intracerebral hemorrhage at baseline and during the 1st and 2nd week: a longitudinal study. Cerebrovasc Dis 23 6 13

25. ZazuliaAR

DiringerMN

VideenTO

AdamsRE

YundtK

2001 Hypoperfusion without ischemia surrounding acute intracerebral hemorrhage. J Cereb Blood Flow Metab 21 804 810

26. HerwehC

JuttlerE

SchellingerPD

KlotzE

JenetzkyE

2007 Evidence against a perihemorrhagic penumbra provided by perfusion computed tomography. Stroke 38 2941 2947

27. ZazuliaAR

VideenTO

PowersWJ

2009 Transient focal increase in perihematomal glucose metabolism after acute human intracerebral hemorrhage. Stroke 40 1638 1643

28. ButcherKS

BairdT

MacGregorL

DesmondP

TressB

2004 Perihematomal edema in primary intracerebral hemorrhage is plasma derived. Stroke 35 1879 1885

29. ZazuliaAR

DiringerMN

DerdeynCP

PowersWJ

1999 Progression of mass effect after intracerebral hemorrhage. Stroke 30 1167 1173

30. GebelJMJr

JauchEC

BrottTG

KhouryJ

SauerbeckL

2002 Natural history of perihematomal edema in patients with hyperacute spontaneous intracerebral hemorrhage. Stroke 33 2631 2635

31. InajiM

TomitaH

ToneO

TamakiM

SuzukiR

2003 Chronological changes of perihematomal edema of human intracerebral hematoma. Acta Neurochir Suppl 86 445 8

32. GebelJM

BrottTG

SilaCA

TomsickTA

JauchE

2000 Decreased perihematomal edema in thrombolysis-related intracerebral hemorrhage compared with spontaneous intracerebral hemorrhage. Stroke 31 596 600

33. SansingLH

KaznatcheevaEA

PerkinsCJ

KomaroffE

GutmanFB

2003 Edema after intracerebral hemorrhage: correlations with coagulation parameters and treatment. J Neurosurg 98 985 992

34. WagnerKR

XiG

HuaY

KleinholzM

de Court

1996 Lobar intracerebral hemorrhage model in pigs: rapid edema development in perihematomal white matter. Stroke 27 490 497

35. LeeKR

KawaiN

KimS

SagherO

HoffJT

1997 Mechanisms of edema formation after intracerebral hemorrhage: effects of thrombin on cerebral blood flow, blood-brain barrier permeability, and cell survival in a rat model. J Neurosurg 86 272 278

36. HuangFP

XiG

KeepRF

HuaY

NemoianuA

2002 Brain edema after experimental intracerebral hemorrhage: role of hemoglobin degradation products. J Neurosurg 96 287 293

37. LevineJM

SniderR

FinkelsteinD

GurolME

ChanderrajR

2007 Early edema in warfarin-related intracerebral hemorrhage. Neurocrit Care 7 58 63

38. WeissSJ

1989 Tissue destruction by neutrophils. N Engl J Med 320 365 376

39. PowerC

HenryS

Del BigioMR

LarsenPH

CorbettD

2003 Intracerebral hemorrhage induces macrophage activation and matrix metalloproteinases. Ann Neurol 53 731 742

40. MayneM

NiW

YanHJ

XueM

JohnstonJB

2001 Antisense oligodeoxynucleotide inhibition of tumor necrosis factor-alpha expression is neuroprotective after intracerebral hemorrhage. Stroke 32 240 248

41. HolminS

MathiesenT

2000 Intracerebral administration of interleukin-1beta and induction of inflammation, apoptosis, and vasogenic edema. J Neurosurg 92 108 120

42. XiG

HuaY

KeepRF

YoungerJG

HoffJT

2001 Systemic complement depletion diminishes perihematomal brain edema in rats. Stroke 32 162 167

43. WangJ

TsirkaSE

2005 Neuroprotection by inhibition of matrix metalloproteinases in a mouse model of intracerebral haemorrhage. Brain 128 1622 1633

44. AyoubT

ChowJ

2008 The conventional autopsy in modern medicine. J R Soc Med 101 177 181

45. JamesML

WarnerDS

LaskowitzDT

2008 Preclinical models of intracerebral hemorrhage: a translational perspective. Neurocrit Care 9 139 152

46. AndaluzN

ZuccarelloM

WagnerKR

2002 Experimental animal models of intracerebral hemorrhage. Neurosurg Clin N Am 13 385 393

47. Stroke Unit Trialists' Collaboration 2007 Organised inpatient (stroke unit) care for stroke. Cochrane Database Syst Rev CD000197

48. CandeliseL

GattinoniM

BersanoA

MicieliG

SterziR

2007 Stroke-unit care for acute stroke patients: an observational follow-up study. Lancet 369 299 305

49. TerentA

AsplundK

FarahmandB

HenrikssonKM

NorrvingB

2009 Stroke unit care revisited: who benefits the most? A cohort study of 105,043 patients in Riks-Stroke, the Swedish Stroke Register. J Neurol Neurosurg Psychiatry 80 881 887

50. DiringerMN

EdwardsDF

2001 Admission to a neurologic/neurosurgical intensive care unit is associated with reduced mortality rate after intracerebral hemorrhage. Crit Care Med 29 635 640

51. HemphillJCIII

NewmanJ

ZhaoS

JohnstonSC

2004 Hospital usage of early do-not-resuscitate orders and outcome after intracerebral hemorrhage. Stroke 35 1130 1134

52. BeckerKJ

BaxterAB

CohenWA

BybeeHM

TirschwellDL

2001 Withdrawal of support in intracerebral hemorrhage may lead to self-fulfilling prophecies. Neurology 56 766 772

53. PrasadK

MendelowAD

GregsonB

2008 Surgery for primary supratentorial intracerebral haemorrhage. Cochrane Database Syst Rev CD000200

54. MendelowAD

GregsonBA

FernandesHM

MurrayGD

TeasdaleGM

2005 Early surgery versus initial conservative treatment in patients with spontaneous supratentorial intracerebral haematomas in the International Surgical Trial in Intracerebral Haemorrhage (STICH): a randomised trial. Lancet 365 387 397

55. ChapmanN

HuxleyR

AndersonC

BousserMG

ChalmersJ

2004 Effects of a perindopril-based blood pressure-lowering regimen on the risk of recurrent stroke according to stroke subtype and medical history: the PROGRESS Trial. Stroke 35 116 121

56. Al-Shahi SalmanR

2009 Haemostatic drug therapies for acute spontaneous intracerebral haemorrhage. Cochrane Database Syst Rev CD005951

57. SteinerT

KasteM

ForstingM

MendelowD

KwiecinskiH

2006 Recommendations for the management of intracranial haemorrhage - part I: spontaneous intracerebral haemorrhage. The European Stroke Initiative Writing Committee and the Writing Committee for the EUSI Executive Committee. Cerebrovasc Dis 22 294 316

58. AndersonCS

HuangY

WangJG

ArimaH

NealB

2008 Intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT): a randomised pilot trial. Lancet Neurol 7 391 399

59. FeiginVL

AndersonN

RinkelGJ

AlgraA

vanGJ

2005 Corticosteroids for aneurysmal subarachnoid haemorrhage and primary intracerebral haemorrhage. Cochrane Database Syst Rev CD004583

60. RighettiE

CelaniMG

CantisaniT

SterziR

BoysenG

2004 Glycerol for acute stroke. Cochrane Database Syst Rev CD000096

61. BereczkiD

FeketeI

PradoGF

LiuM

2007 Mannitol for acute stroke. Cochrane Database Syst Rev CD001153

62. LydenPD

ShuaibA

LeesKR

DavalosA

DavisSM

2007 Safety and tolerability of NXY-059 for acute intracerebral hemorrhage: the CHANT Trial. Stroke 38 2262 2269

63. HaleyECJr

ThompsonJL

LevinB

DavisS

LeesKR

2005 Gavestinel does not improve outcome after acute intracerebral hemorrhage: an analysis from the GAIN International and GAIN Americas studies. Stroke 36 1006 1010

64. GeeganageC

BathPM

2008 Interventions for deliberately altering blood pressure in acute stroke. Cochrane Database Syst Rev CD000039

65. SorimachiT

FujiiY

MoritaK

TanakaR

2005 Rapid administration of antifibrinolytics and strict blood pressure control for intracerebral hemorrhage. Neurosurgery 57 837 844

66. OjacastroMF

TabuenaMP

DulosID

TabuenaRP

2008 Efficacy of tranexamic acid in reducing hematoma volume in patients with hypertensive intracerebral hemorrhage. Int J Stroke 3 197 198 (abstract)

67. CucchiaraB

MesseS

SansingL

KasnerS

LydenP

2008 Hematoma growth in oral anticoagulant related intracerebral hemorrhage. Stroke 39 2993 2996

68. AguilarMI

HartRG

KaseCS

FreemanWD

HoebenBJ

2007 Treatment of warfarin-associated intracerebral hemorrhage: literature review and expert opinion. Mayo Clin Proc 82 82 92

69. ThompsonBB

BejotY

CasoV

CastilloJ

ChristensenH

2010 Prior antiplatelet therapy and outcome following intracerebral hemorrhage. A systematic review. Neurology Epub ahead of print. doi:WNL.0b013e3181f735e5v1

70. GreenbergSM

RosandJ

SchneiderAT

CreedPL

GandySE

2006 A phase 2 study of tramiprosate for cerebral amyloid angiopathy. Alzheimer Dis Assoc Disord 20 269 274

71. KolstoeSE

RidhaBH

BellottiV

WangN

RobinsonCV

2009 Molecular dissection of Alzheimer's disease neuropathology by depletion of serum amyloid P component. Proc Natl Acad Sci U S A 106 7619 7623

72. OrgogozoJM

GilmanS

DartiguesJF

LaurentB

PuelM

2003 Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 61 46 54

73. FrantziasJ

SenaES

MacleodMR

Al-Shahi SalmanR

2010 Treatment of intracerebral hemorrhage in animal models: Meta-analysis Ann Neurol In press

74. NakamuraT

KeepRF

HuaY

SchallertT

HoffJT

2004 Deferoxamine-induced attenuation of brain edema and neurological deficits in a rat model of intracerebral hemorrhage. J Neurosurg 100 672 678

75. GuY

HuaY

KeepRF

MorgensternLB

XiG

2009 Deferoxamine reduces intracerebral hematoma-induced iron accumulation and neuronal death in piglets. Stroke 40 2241 2243

76. NINDS ICH Workshop Participants 2005 Priorities for clinical research in intracerebral hemorrhage: report from a National Institute of Neurological Disorders and Stroke workshop. Stroke 36 e23 e41

77. HeroldS

vonKR

JaegerC

1982 Follow-up of spontaneous intracerebral haemorrhage by computed tomography. J Neurol 228 267 276

78. KelleyRE

BergerJR

ScheinbergP

StokesN

1982 Active bleeding in hypertensive intracerebral hemorrhage: computed tomography. Neurology 32 852 856

79. SilvaY

LeiraR

TejadaJ

LainezJM

CastilloJ

2005 Molecular signatures of vascular injury are associated with early growth of intracerebral hemorrhage. Stroke 36 86 91

80. JauchEC

LindsellCJ

AdeoyeO

KhouryJ

BarsanW

2006 Lack of evidence for an association between hemodynamic variables and hematoma growth in spontaneous intracerebral hemorrhage. Stroke 37 2061 2065

81. QureshiAI

PaleschYY

MartinR

NovitzkeJ

Cruz-FloresS

2010 Effect of systolic blood pressure reduction on hematoma expansion, perihematomal edema, and 3-month outcome among patients with intracerebral hemorrhage: results from the antihypertensive treatment of acute cerebral hemorrhage study. Arch Neurol 67 570 576

Štítky
Interní lékařství

Článek vyšel v časopise

PLOS Medicine


2010 Číslo 10

Nejčtenější v tomto čísle

Tomuto tématu se dále věnují…


Kurzy

Zvyšte si kvalifikaci online z pohodlí domova

Léčba bolesti v ordinaci praktického lékaře
nový kurz
Autoři: MUDr. PhDr. Zdeňka Nováková, Ph.D.

Revmatoidní artritida: včas a k cíli
Autoři: MUDr. Heřman Mann

Jistoty a nástrahy antikoagulační léčby aneb kardiolog - neurolog - farmakolog - nefrolog - právník diskutují
Autoři: doc. MUDr. Štěpán Havránek, Ph.D., prof. MUDr. Roman Herzig, Ph.D., doc. MUDr. Karel Urbánek, Ph.D., prim. MUDr. Jan Vachek, MUDr. et Mgr. Jolana Těšínová, Ph.D.

Léčba akutní pooperační bolesti
Autoři: doc. MUDr. Jiří Málek, CSc.

Nové antipsychotikum kariprazin v léčbě schizofrenie
Autoři: prof. MUDr. Cyril Höschl, DrSc., FRCPsych.

Všechny kurzy
Kurzy Doporučená témata Časopisy
Přihlášení
Zapomenuté heslo

Nemáte účet?  Registrujte se

Zapomenuté heslo

Zadejte e-mailovou adresu se kterou jste vytvářel(a) účet, budou Vám na ni zaslány informace k nastavení nového hesla.

Přihlášení

Nemáte účet?  Registrujte se